Understanding SUCLA2: A Potential Drug Target for Neural Stem Cells

Target Name: SUCLA2

NCBI ID: G8803

SUCLA2

Understanding SUCLA2: A Potential Drug Target for Neural Stem Cells

SUCLA2 (SUCB1_HUMAN) is a protein that is expressed in various tissues throughout the body, including the brain, spinal cord, and peripheral tissues. It is a member of the happy life family, which includes other proteins that are involved in the development and maintenance of neural stem cells.

SUCLA2 plays a crucial role in the development and maintenance of neural stem cells, which are a type of cell that is responsible for the growth, repair, and replacement of damaged or lost cells in the nervous system. These stem cells are essential for the healthy functioning of the nervous system, and they are often targeted by drugs in order to treat a variety of neurological conditions.

One of the key functions of SUCLA2 is its role in the development and maintenance of neural stem cells. This protein is involved in the process of stem cell self-renewal, which is the ability of stem cells to continuously divide and multiply.

SUCLA2 is also involved in the process of stem cell differentiation, which is the ability of stem cells to develop into different types of cells in the nervous system. This is important for the development of new neurons and the repair of damaged tissue.

In addition to its role in stem cell development and maintenance, SUCLA2 is also involved in the regulation of neural stem cell survival. This protein helps to ensure that stem cells are able to survive and continue to divide in the face of various stressors, such as inflammation or stress.

The study of SUCLA2 and its role in neural stem cells has important implications for the development of new treatments for a variety of neurological conditions. By targeting this protein with drugs, researchers hope to be able to treat conditions such as cancer, neurodegenerative diseases, and injuries.

Overall, SUCLA2 is a drug target and biomarker that has the potential to revolutionize our understanding of the nervous system and the development of new treatments. Further research is needed to fully understand its role and potential applications.

Protein Name: Succinate-CoA Ligase ADP-forming Subunit Beta

Functions: ATP-specific succinyl-CoA synthetase functions in the citric acid cycle (TCA), coupling the hydrolysis of succinyl-CoA to the synthesis of ATP and thus represents the only step of substrate-level phosphorylation in the TCA (PubMed:15877282). The beta subunit provides nucleotide specificity of the enzyme and binds the substrate succinate, while the binding sites for coenzyme A and phosphate are found in the alpha subunit (By similarity)

The "SUCLA2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SUCLA2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets